Ann: Imugene to Present at Annual JPMorgan Healthcare Conference, page-61

Hi Jov

Like you, I am also curious ...

"Curious as to why they’ve left out the fact they have just achieved FDA Fast Track designation for CF33s expansion trial."

I will be amazed if it doesn't get some sort of mention.

The slides show unpacks aze-cel first which may suggest that IMU sees this being 'first to market'. Just my assumption.

Ver-Vaxx still being promoted so that is encouraging.

You would have to say, that even though there is no new data since November, the MAST study will look very impressive
to the audience.

The whole presentation, when seen across all studies, is very impressive. Certainly too much to fully comprehend in one session,
so I would expect that LC will be encouraging delegates to join her and the team in follow-up meetings. It will be in the
'follow-ups' that the 'real work' will begin. It will take time, and any announcement will drop without warning.

All opinion